Trials / Recruiting
RecruitingNCT07011186
A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies
A Phase Ib/II Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of TQB3909 Tablets in Combination With Azacitidine in Subjects With Myeloid Malignancies
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 138 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open, multi-center clinical study designed to evaluate the safety, tolerability and efficacy of TQB3909 tablets in combination with azacitidine in subjects with myeloid malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB3909 Tablets + Azacitidine | TQB3909 is a protein inhibitor; Azacitidine is a cytidine nucleoside analogue |
Timeline
- Start date
- 2024-04-17
- Primary completion
- 2025-10-01
- Completion
- 2026-10-01
- First posted
- 2025-06-08
- Last updated
- 2025-06-08
Locations
21 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07011186. Inclusion in this directory is not an endorsement.